Monoclonal Antibodies as SARS-CoV-2 Serology Standards: Experimental Validation and Broader Implications for Correlates of Protection

Int J Mol Sci. 2023 Oct 28;24(21):15705. doi: 10.3390/ijms242115705.

Abstract

COVID-19 has highlighted challenges in the measurement quality and comparability of serological binding and neutralization assays. Due to many different assay formats and reagents, these measurements are known to be highly variable with large uncertainties. The development of the WHO international standard (WHO IS) and other pool standards have facilitated assay comparability through normalization to a common material but does not provide assay harmonization nor uncertainty quantification. In this paper, we present the results from an interlaboratory study that led to the development of (1) a novel hierarchy of data analyses based on the thermodynamics of antibody binding and (2) a modeling framework that quantifies the probability of neutralization potential for a given binding measurement. Importantly, we introduced a precise, mathematical definition of harmonization that separates the sources of quantitative uncertainties, some of which can be corrected to enable, for the first time, assay comparability. Both the theory and experimental data confirmed that mAbs and WHO IS performed identically as a primary standard for establishing traceability and bridging across different assay platforms. The metrological anchoring of complex serological binding and neuralization assays and fast turn-around production of an mAb reference control can enable the unprecedented comparability and traceability of serological binding assay results for new variants of SARS-CoV-2 and immune responses to other viruses.

Keywords: SARS-CoV-2; WHO international standard (WHO IS); harmonization; monoclonal antibody; neutralization assay; normalization; result comparability and traceability; serological binding assay; spike protein; uncertainty quantification.

MeSH terms

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Biological Assay
  • COVID-19*
  • Data Analysis
  • Humans
  • SARS-CoV-2*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Antibodies, Neutralizing

Grants and funding

This research received no external funding.